Article
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer.
Signal transduction and targeted therapy - 12 Sept 2025
Lu Jun, Hu Minjuan, Zhao Yikai, Chu Tianqing, Zhang Wei, Zhou Yijia, Cai Xinlei, Wu Jun, Hu Liang, Shi Chunlei, Xiong Liwen, Gu Aiqin, Wang Huimin, Zhang Yanwei, Lou Yuqing, Zhong Runbo, Gao Zhiqiang, Liu Hongyu, Zhou Chao, Wu Yingli, Zhu Liang, Zhong Hua, Ji Hongbin, Han Baohui
Abstract excerpt
Oncogenic KRAS mutations are frequently detected in NSCLC. It remains a major challenge to target all KRAS mutants. MEK inhibitors are considered candidates for treating KRAS-mutant NSCLC; however, their easy adaptive resistance precludes further application. Here, we found that MEK inhibitor-trametinib treatment results in the feedback activation of multiple receptor tyrosine kinases (RTKs) and that treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.